Detalhe da pesquisa
1.
A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis.
Rheumatology (Oxford)
; 2023 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37471590
2.
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.
J Neurol Neurosurg Psychiatry
; 94(1): 1-9, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36418156
3.
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years.
Mod Rheumatol
; 33(1): 64-72, 2023 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35365828
4.
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
Ann Rheum Dis
; 81(2): 184-192, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34740884
5.
Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).
Mod Rheumatol
; 32(1): 59-67, 2022 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33274687
6.
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
Ann Rheum Dis
; 80(7): 848-858, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33504485
7.
Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors.
Rheumatology (Oxford)
; 60(11): 4991-5001, 2021 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33871596
8.
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
Ann Rheum Dis
; 79(10): 1290-1297, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32788396
9.
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Rheumatology (Oxford)
; 59(12): 3834-3844, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32449924
10.
Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.
Rheumatology (Oxford)
; 59(2): 292-302, 2020 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31312844
11.
Unique Sjögren's syndrome patient subsets defined by molecular features.
Rheumatology (Oxford)
; 59(4): 860-868, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31497844
12.
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Lancet
; 391(10139): 2513-2524, 2018 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29908670
13.
Baricitinib in Patients with Refractory Rheumatoid Arthritis.
N Engl J Med
; 374(13): 1243-52, 2016 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-27028914
14.
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
Ann Rheum Dis
; 78(11): 1454-1462, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31362993
15.
Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study.
Ann Rheum Dis
; 78(2): 171-178, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30194275
16.
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
JAMA
; 322(4): 315-325, 2019 07 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31334793
17.
Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.
Rheumatology (Oxford)
; 57(11): 2001-2011, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30053162
18.
Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis.
Rheumatology (Oxford)
; 57(11): 1972-1981, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30032191
19.
Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.
Rheumatology (Oxford)
; 57(8): 1423-1431, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29746672
20.
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.
Rheumatology (Oxford)
; 57(5): 900-908, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29415145